Paris, July 3, 2025 – BrainEver, a biotechnology company focused on neurodegenerative diseases, today announced the successful completion of its €33 million Series B financing round. This funding will support the launch of the company’s first clinical trial in Europe for its lead therapeutic candidate targeting amyotrophic lateral sclerosis (ALS). The round was co-led by Critical Path Ventures and the European Innovation Council (EIC), with continued support from existing in